Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Touchstone Plays Tough As IP Group Ups Bid To £490m

Executive Summary

One of the key attractions is Touchstone's holdings in Imperial College spin-offs such as Cell Medica, Circassia Pharmaceuticals and TopiVert Pharma.

You may also be interested in...



Deal Watch: Valeant Continues Divestment Spree By Selling Obagi At A Loss

Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.

Mite Trial Failure 'The Final Straw' As Circassia Ends Anti-Allergy Investing

Circassia has thrown in the towel on investing in anti-allergy vaccines and will focus now on respiratory activities, after its house dust mite allergy study missed its primary endpoints.

Cell Medica Targeting Next CAR-T Wave: Solid Tumor Anticancers

Cell Medica has just raised a large Series C from UK institutional investors to explore the use of novel cell-based immunotherapies in solid tumors, a “new chapter” for this class of therapeutic agents.

Topics

Related Companies

UsernamePublicRestriction

Register

SC099156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel